ACTELION IS A FULLY-INTERGRATED BIOPHARMACEUTICAL COMPANY WITH INNOVATION AT ITS CORE.
Actelion is the leader in the science and medicine of pulmonary arterial hypertension (PAH), with over 15 years of experience. With an in depth understanding of the complex pathways and molecular mechanisms of this disease, Actelion has successfully developed tailored medicines that can make a real difference to patient outcomes.
Innovative products Veletri, Opsumit assure Actelion’s leadership in the field of PAH into the mid-2020s, with their candidate product selexipag, developed in partnership with Nippon Shinyaku, currently under review with Health Authorities.
In depth expertise in human biology, especially the knowledge of specific families of molecular targets, such as G-Protein Coupled Receptors, led Actelion to Opsumit and it is this knowledge that will take the company to new areas.
Actelion leverages our scientific expertise through in-house discovery, development and marketing talents; ‘fully-integrated’ also means that they have all the expertise in all areas of the value chain for delivering great products to physicians, patients, payors – as well as all the support functions and infrastructure needed to deliver their ambition efficiently.
Contact Details
Actelion Ilac Ltd.Sti.
Kurucesme Cad. Kirbac Sok. No:17/4
Kurucesme 34345 Istanbul
Turkiye
Phone: +90 212 362 10 00
Fax: +90 212 257 02 67
Turkey has been a high priority market for Actelion since the company’s relatively recent beginnings, and the general manager of the local affiliate discusses his affiliate efforts to improve awareness…
The founder and chairman of the rapidly expanding World Medicine group of companies discusses his firm’s international expansion strategy, how he came to the decision to invest in production and…
The secretary general of the innovators’ association gives an overview of the current structural challenges facing the pharmaceutical industry in Turkey, and discusses the changes that need to be introduced…
Menarini’s Turkish subsidiary, Ibrahim Etem Menarini, has adapted to the current pharmaceutical market and is positioned to grow in several segments including their new OTC business, but is constrained by…
Dogan Taşkent, president of the Swiss Chamber of Commerce in Turkey discusses the most successful models for innovation in Turkey, the current status of start-up incubators in the country, and…
Lundbeck Turkey’s managing director discusses CNS and mental illness in Turkey, and their recent development of manufacturing operations in Turkey for their new product. Given this specialization in and deep…
Pfizer Turkey has taken a strong supporting role in Turkey’s current strategic development plan by localizing the production of their Prix Galien winning Prevnar vaccine. Country Manager Elif Aral discusses…
The chairman of the British Chamber of Commerce in Turkey, the second oldest foreign British chamber in the world, discusses their efforts to increase investment in high value added services…
Genzyme Turkey’s general manager discusses diagnosis and treatment access issues for rare diseases, the need for prioritization of patient welfare in all aspects of health policy, and the importance of…
UCB’s managing director for Turkey and the MEA region discusses UCB’s leading patient centricity, how UCB is addressing gaps in the Turkish healthcare system surrounding epileptic patients, and the company’s plan…
Fatma Taman, Chair of ISPE and General Manager of PharmaVision, discusses the importance of proper education and training within the pharmaceutical industry to ensure the sector’s sustainable growth and development.…
The president of Turkey’s oldest pharmaceutical industry association discusses the government’s reluctance to reform the pricing system, and how this is causing the absorption of the domestic Turkish pharmaceutical industry…
The secretary general of the association representing Turkish private hospitals dicusses the private sector’s role in the Turkish healthcare system, as a subset of hospitals with a particularly high standards…
See our Cookie Privacy Policy Here
